Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC).

Daniel Vargas Pivato de Almeida,Justine Anderson,Daniel C. Danila,Michael J. Morris,Susan F. Slovin,Wassim Abida,Erica Simone Dayan,Tracy Curley,Gabrielle Arauz,Raymond E. Baser,Howard I. Scher,Karen A. Autio

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC).

2020

Daniel Vargas Pivato de Almeida
Justine Anderson
Daniel C. Danila
Michael J. Morris
Susan F. Slovin
Wassim Abida
Erica Simone Dayan
Tracy Curley
Gabrielle Arauz
Raymond E. Baser
Howard I. Scher
Karen A. Autio

e24174Background: Incorporation of the PRO-CTCAE during chemotherapy is associated with fewer ER visits and improved survival. Limited data exist using this tool to capture irAE in immunotherapy tr...

Keywords:

Oncology
Castration-sensitive prostate cancer
Common Terminology Criteria for Adverse Events
Physical therapy
pro ctcae
Immune system
Ipilimumab
Internal medicine
Phases of clinical research
Medicine
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations